IP Library › Granted Patent US 10,092,554
Granted Patent B2
US 10,092,554 · App. 14/698,920 · Granted Oct 9, 2018

Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Inventors: Daniel Cohen (Saint Cloud, FR); Ilya Chumakov (Vaux-le-Penil, FR); Serguei Nabirochkin (Chatenay-Malabry, FR); Rodolphe Hajj (Saint Germain En Laye, FR)
Assignee: PHARNEXT
A61K31/445A61K31/155A61K31/164A61K31/196A61K31/197A61K31/435A61K31/44A61K31/48A61K31/519A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,554
App. No.
14/698,920
Granted
Oct 9, 2018
Kind
B2
Abstract

The present invention relates to compositions and methods for controlling glycemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies for diabetes and related disorders, based on compositions controlling the blood glucose level.

Claims (23)

1. A method for treating diabetes or a related disease selected from impaired glucose tolerance, impaired fasting glucose, insulin resistance, metabolic syndrome, postprandial hyperglycemia and overweight or obesity in a mammalian subject in need thereof, comprising administering to said subject an effective amount of a composition comprising:

ifenprodil and fenspiride,

fenspiride and torasemide,

fenspiride and triamterene, or

fenspiride and tolfenamic acid,

or salt(s), prodrug(s), or sustained release formulation(s) thereof.

2. The method of claim 1 , further comprising administering to said subject at least one anti-diabetic agent.

3. The method of claim 2 , wherein the at least one anti-diabetic agent is selected from acarbose, acetohexamide, alogliptin, berberine, bezafibrate, bromocriptine, buformin, carbutamide, chlorpropamide, chromium picolinate, ciprofibrate, clofibrate, colesevelam, dexfenfluramine, dutogliptin, exenatide, fenofibrate, gemfibrozil, gemigliptin, glibenclamide, glibornuride, glicetanile, gliclazide, glimepiride, glipizide, gliquidone, glisentide, glyclopyramide, imidapril, insulin, inulin, lipoic acid, linagliptin, liraglutide, mecobalamin, metformin, miglitol, mitiglinide, nateglinide, orlistat, phenformin, pioglitazone, pramlintide, repaglinide, rosiglitazone, saxagliptin, sitagliptin, tolazamide, tolbutamide, vildagliptin or voglibose, or salt(s), prodrug(s), or sustained release formulation(s) thereof.

4. The method of claim 3 , wherein the at least one anti-diabetic agent is metformin, or a salt, prodrug, or sustained release formulation thereof.

5. The method of claim 4 comprising administering to said subject:

ifenprodil and fenspiride and metformin,

fenspiride and torasemide and metformin,

fenspiride and triamterene and metformin, or

fenspiride and tolfenamic acid and metformin,

or salt(s), prodrug(s), or sustained release formulation(s) thereof.

6. A method for controlling blood glucose level in a mammalian subject in need thereof, comprising administering to said subject a composition comprising fenspiride, or a salt, prodrug or a sustained release formulation thereof in combination with at least one further compound selected from ifenprodil, torasemide, triamterene, tolfenamic acid, or salt(s), prodrug(s) or sustained release formulation(s) thereof.

7. The method of claim 6 , wherein the mammalian subject is suffering from diabetes or from a related disorder selected from impaired glucose tolerance, impaired fasting glucose, insulin resistance, metabolic syndrome, postprandial hyperglycemia and overweight or obesity.

8. A method for decreasing insulin resistance in a mammalian subject in need thereof, comprising administering to said subject a composition comprising fenspiride, or a salt, prodrug or a sustained release formulation thereof in combination with at least one further compound selected from ifenprodil, torasemide, triamterene, tolfenamic acid, or salt(s), prodrug(s) or sustained release formulation(s) thereof.

9. A method for increasing or stimulating glucose uptake in adipocytes or muscular cells in a mammalian subject in need thereof, comprising administering to said subject a composition comprising fenspiride or a salt, prodrug or a sustained release formulation thereof in combination with at least one further compound selected from ifenprodil, torasemide, triamterene, tolfenamic acid, or salt(s), prodrug(s) or sustained release formulation(s) thereof.

10. The method of claim 1 , wherein the mammalian subject is suffering from type 2 diabetes.

11. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier or excipient.

12. The method of claim 1 , wherein the compounds are formulated or administered together, separately or sequentially.

13. The method of claim 1 , wherein the composition is administered repeatedly to the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2015
From: COHEN, DANIEL; CHUMAKOV, ILYA; NABIROCHKIN, SERGUEI; HAJJ, RODOLPHE
To: PHARNEXT
Reel/Frame 036195/0214 →
Priority Claims (1)
EP 12306354 · Oct 30, 2012 · regional
Continuity (3)
Continuation In Part PCTEP2013072728 · Oct 30, 2013
Provisional Application 61720156 · Oct 30, 2012
Related Publication 20150231123A1 · Aug 20, 2015